ArticleBMC neurology2026

Two mild phenotype molybdenum cofactor deficiency patients with novel MOCS2 mutation and immunological treatment after COVID-19 infection.

Zhen Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.